China-based gene sequencing specialist MGI Tech Co., Ltd (SHA: 688114) has partnered with OC Medicina de Precisão of Oncoclínicas&Co, Latin America’s largest cancer treatment group. The collaboration aims to promote precision medicine innovation in Brazil, offering efficient and personalized cancer diagnosis and treatment.
Partnership Details
The partnership combines OC Medicina de Precisão’s tumor diagnosis and treatment management system with MGI’s advanced sequencing technology. MGI’s DNBSEQ-G400 genomic sequencer enables rapid sequencing, allowing comprehensive genetic profiling to detect cancer predispositions and identify mutations for targeted therapies.
Oncoclínicas&Co Background
Founded in 2010, Oncoclínicas&Co is a leading oncology, hematology, and radiation therapy center in Latin America. The company’s integration of MGI’s technology enhances its ability to provide personalized oncology solutions.
MGI’s Brazil Expansion
MGI previously partnered with Brazilian firms Dasa and Sabin Group in 2024, solidifying its presence in Latin America’s medical diagnostics market.-Fineline Info & Tech
Leave a Reply